Blinatumomab After Frontline R-Chemotherapy in Adults With Newly Diagnosed, High-Risk DLBCL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia and Lymphoma
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL
Leukemia and Lymphoma 2022 May 03;[EPub Ahead of Print], DA Katz, JD Morris, MP Chu, KA David, C Thieblemont, NJ Morley, SS Khan, A Viardot, A Martín García-Sancho, G Rodríguez-García, M Bastos-Oreiro, ST Lee, W Kormany, Y Chen, HL Wong, AA Anderson, Y Katlinskaya, AA Avilion, T Dai, E González-BarcaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.